keyword
MENU ▼
Read by QxMD icon Read
search

Treatment Resistant Depression

keyword
https://www.readbyqxmd.com/read/29025428/compound-heterozygosity-for-two-ghr-missense-mutations-in-a-patient-affected-by-laron-syndrome-a-case-report
#1
Stefania Moia, Daniele Tessaris, Silvia Einaudi, Luisa de Sanctis, Gianni Bona, Simonetta Bellone, Flavia Prodam
BACKGROUND: Mutations localized in the Growth Hormone Receptor (GHR) gene are often associated with the pathogenesis of Laron Syndrome, an autosomal recessive hereditary disorder characterized by severe growth retardation. Biochemically, patients present normal to high circulating GH levels, in presence of very low or undetectable IGF-I levels, which do not rise after rhGH treatment. CASE PRESENTATION: We describe the case of a 3.8 years old girl with symmetrical short stature (-3...
October 12, 2017: Italian Journal of Pediatrics
https://www.readbyqxmd.com/read/29020098/treatment-with-high-dose-antidepressants-severely-exacerbates-the-pathological-outcome-of-experimental-escherichia-coli-infections-in-poultry
#2
Sofie Kromann, Egle Kudirkiene, Lili Li, Ida Thoefner, Elisabeth Daldorph, Jens Peter Christensen, Hecheng Meng, Rikke Heidemann Olsen
There is an urgent need for novel antibiotics as the current antibiotics are losing their value due to increased resistance among clinically important bacteria. Sertraline, an on-marked anti-depressive drug, has been shown to modify bacterial activity in vitro, including increasing the susceptibility of Escherichia coli to antibiotics. The aim of the present study was to investigate if the antimicrobial activity of sertraline could be documented under clinical settings, hereunder if sertraline could potentiate the effect of tetracycline in treatment of an experimentally induced ascending infection in poultry...
2017: PloS One
https://www.readbyqxmd.com/read/29018554/psychiatric-neurosurgery-in-the-21st-century-overview-and-the-growth-of-deep-brain-stimulation
#3
REVIEW
Kenneth Barrett
Ambulatory deep brain stimulation (DBS) became possible in the late 1980s and was initially used to treat people with movement disorders. Trials of DBS in people with treatment-resistant psychiatric disorder began in the late 1990s, initially focusing on obsessive-compulsive disorder, major depressive disorder and Tourette syndrome. Despite methodological issues, including small participant numbers and lack of consensus over brain targets, DBS is now being trialled in a wide range of psychiatric conditions...
October 2017: BJPsych Bulletin
https://www.readbyqxmd.com/read/29017334/brexpiprazole-a-new-leaf-on-the-partial-dopamine-agonist-branch
#4
Judy Hope, David Castle, Nicholas A Keks
OBJECTIVES: Brexpiprazole is a new dopamine partial agonist antipsychotic in the same class as aripiprazole. This paper will briefly review brexpiprazole and compare it with aripiprazole. CONCLUSIONS: Brexpiprazole and aripiprazole are both partial agonists at dopamine D2, and serotonin 5-HT1A and antagonists at serotonin 5-HT2A and noradrenergic α1B receptors. However, the two drugs are significantly different in potencies at various receptors; neurochemical profiles predict that brexpiprazole may be comparable with aripiprazole in its antipsychotic efficacy but may cause less akathisia, extrapyramidal side effects (EPS) and activation...
October 1, 2017: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/28994451/efficacy-of-the-danish-epilepsy-surgery-programme
#5
E Holm, M T Foged, S Beniczky, B Jespersen, J Brennum, L H Pinborg
OBJECTIVE: Despite optimal medical treatment, approximately one-third of patients with epilepsy continue to have seizures. Epilepsy surgery is widely accepted as a therapeutic option in the selected subset of patients with drug-resistant focal epilepsy. Here, we report the results of the Danish epilepsy surgery programme from 2009 to 2014. MATERIAL AND METHODS: A total of 169 consecutive patients, operated at Rigshospitalet, were included. Information was gathered from digital patient records...
October 10, 2017: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/28993946/tobacco-alpha-expansin-expa4-plays-a-role-in-nicotiana-benthamiana-defence-against-tobacco-mosaic-virus
#6
Li-Juan Chen, Wen-Shan Zou, Guo Wu, Hong-Hui Lin, De-Hui Xi
Tobacco EXPA4 plays a role in Nicotiana benthamiana defence against virus attack and affects antioxidative metabolism and phytohormone-mediated immunity responses in tobacco. Expansins are cell wall-loosening proteins known for their endogenous functions in cell wall extensibility during plant growth. The effects of expansins on plant growth, developmental processes and environment stress responses have been well studied. However, the exploration of expansins in plant virus resistance is rarely reported. In the present study, virus-induced gene silencing (VIGS) and Agrobacterium-mediated transient overexpression were conducted to investigate the role of Nicotiana tabacum alpha-expansin 4 (EXPA4) in modulating Tobacco mosaic virus (TMV-GFP) resistance in Nicotiana benthamiana...
October 9, 2017: Planta
https://www.readbyqxmd.com/read/28991067/a-6-month-follow-up-case-study-of-low-frequency-right-prefrontal-repetitive-transcranial-magnetic-stimulation-in-treatment-resistant-bipolar-depression
#7
Shinsuke Kito, Yuki Matsuda, Yurie Sewaki, Junpei Sekiya, Takeshi Fujii, Takamasa Noda, Satoru Ikezawa, Harumasa Takano, Kanako Nakazawa, Mami Nomura, Shiori Setoyama, Kazuyuki Nakagome
No abstract text is available yet for this article.
October 3, 2017: Journal of ECT
https://www.readbyqxmd.com/read/28989100/pleiotropic-genes-in-psychiatry-calcium-channels-and-the-stress-related-fkbp5-gene-in-antidepressant-resistance
#8
Chiara Fabbri, Filippo Corponi, Diego Albani, Ilaria Raimondi, Gianluigi Forloni, Koen Schruers, Siegfried Kasper, Alexander Kautzky, Joseph Zohar, Daniel Souery, Stuart Montgomery, Carlotta Pia Cristalli, Vilma Mantovani, Julien Mendlewicz, Alessandro Serretti
A candidate gene and a genome-wide approach were combined to study the pharmacogenetics of antidepressant response and resistance. Investigated genes were selected on the basis of pleiotropic effect across psychiatric phenotypes in previous genome-wide association studies and involvement in antidepressant response. Three samples with major depressive disorder (total=671) were genotyped for 44 SNPs in 8 candidate genes (CACNA1C, CACNB2, ANK3, GRM7, TCF4, ITIH3, SYNE1, FKBP5). Phenotypes were response/remission after 4weeks of treatment and treatment-resistant depression (TRD)...
October 5, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28988904/subcallosal-cingulate-deep-brain-stimulation-for-treatment-resistant-depression-a-multisite-randomised-sham-controlled-trial
#9
Paul E Holtzheimer, Mustafa M Husain, Sarah H Lisanby, Stephan F Taylor, Louis A Whitworth, Shawn McClintock, Konstantin V Slavin, Joshua Berman, Guy M McKhann, Parag G Patil, Barry R Rittberg, Aviva Abosch, Ananda K Pandurangi, Kathryn L Holloway, Raymond W Lam, Christopher R Honey, Joseph S Neimat, Jaimie M Henderson, Charles DeBattista, Anthony J Rothschild, Julie G Pilitsis, Randall T Espinoza, Georgios Petrides, Alon Y Mogilner, Keith Matthews, DeLea Peichel, Robert E Gross, Clement Hamani, Andres M Lozano, Helen S Mayberg
BACKGROUND: Deep brain stimulation (DBS) of the subcallosal cingulate white matter has shown promise as an intervention for patients with chronic, unremitting depression. To test the safety and efficacy of DBS for treatment-resistant depression, a prospective, randomised, sham-controlled trial was conducted. METHODS: Participants with treatment-resistant depression were implanted with a DBS system targeting bilateral subcallosal cingulate white matter and randomised to 6 months of active or sham DBS, followed by 6 months of open-label subcallosal cingulate DBS...
October 4, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28981882/electroconvulsive-therapy-selectively-enhanced-feedforward-connectivity-from-fusiform-face-area-to-amygdala-in-major-depressive-disorder
#10
Jiaojian Wang, Qiang Wei, Tongjian Bai, Xiaoqin Zhou, Hui Sun, Benjamin Becker, Yanghua Tian, Kai Wang, Keith Kendrick
Electroconvulsive therapy (ECT) has been widely used to treat the major depressive disorder (MDD), especially for treatment resistant depression. However, the neuroanatomical basis of ECT remains an open problem. In our study, we combined the voxel-based morphology (VBM), resting-state functional connectivity (RSFC), and granger causality analysis (GCA) to identify the longitudinal changes of structure and function in 23 MDD patients before and after ECT. In addition, multivariate pattern analysis using linear support vector machine (SVM) was applied to classify 23 depressed patients from 25 gender, age, and education matched healthy controls...
August 28, 2017: Social Cognitive and Affective Neuroscience
https://www.readbyqxmd.com/read/28977521/the-impact-of-bdnf-polymorphisms-on-suicidality-in-treatment-resistant-major-depressive-disorder-a-european-multicenter-study
#11
Alexandra Schosser, Laura Carlberg, Raffaella Calati, Alessandro Serretti, Isabel Massat, Christoph Spindelegger, Sylvie Linotte, Julien Mendlewicz, Daniel Souery, Joseph Zohar, Stuart Montgomery, Siegfried Kasper
Background: Numerous studies have reported associations between the brain-derived neurotrophic factor (BDNF) gene and psychiatric disorders, including suicidal behavior, although with conflicting results. Methods: A total of 250 major depressive disorder patients were collected in the context of a European multicenter resistant depression study and treated with antidepressants at adequate doses for at least 4 weeks. Suicidality was assessed using the Mini International Neuropsychiatric Interview and Hamilton Rating Scale for Depression, and treatment response using the HAM-D...
October 1, 2017: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28975710/specific-depressive-symptoms-predict-remission-to-aripiprazole-augmentation-in-late-life-treatment-resistant-depression
#12
Marie Anne Gebara, Elizabeth A DiNapoli, John Kasckow, Jordan F Karp, Daniel M Blumberger, Eric J Lenze, Benoit H Mulsant, Charles F Reynolds
OBJECTIVE: To identify which specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression. METHODS: This is a secondary analysis of data from a late-life treatment resistant depression trial examining the safety and efficacy of aripiprazole augmentation. Participants aged 60 and above were randomized to aripiprazole augmentation (N = 91) versus placebo (N = 90). The main outcome was depression remission...
October 3, 2017: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28967437/corrigendum-to-continuation-phase-intravenous-ketamine-in-adults-with-treatment-resistant-depression-j-affect-disord-206-2016-300-304
#13
Jennifer L Vande Voort, Robert J Morgan, Simon Kung, Keith G Rasmussen, Jose Rico, Brian A Palmer, Kathryn M Schak, Susannah J Tye, Matthew J Ritter, Mark A Frye, William V Bobo
No abstract text is available yet for this article.
September 26, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28965430/deep-brain-stimulation-for-severe-treatment-resistant-obsessive-compulsive-disorder-an-open-label-case-series
#14
Sarah Farrand, Andrew H Evans, Simone Mangelsdorf, Samantha M Loi, Ramon Mocellin, Adam Borham, JoAnne Bevilacqua, Scott Blair-West, Mark A Walterfang, Richard G Bittar, Dennis Velakoulis
OBJECTIVE: Deep brain stimulation can be of benefit in carefully selected patients with severe intractable obsessive-compulsive disorder. The aim of this paper is to describe the outcomes of the first seven deep brain stimulation procedures for obsessive-compulsive disorder undertaken at the Neuropsychiatry Unit, Royal Melbourne Hospital. The primary objective was to assess the response to deep brain stimulation treatment utilising the Yale-Brown Obsessive Compulsive Scale as a measure of symptom severity...
September 1, 2017: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/28962608/benefits-of-home-based-multidisciplinary-exercise-and-supportive-care-in-inoperable-non-small-cell-lung-cancer-protocol-for-a-phase-ii-randomised-controlled-trial
#15
Lara Edbrooke, Sanchia Aranda, Catherine L Granger, Christine F McDonald, Mei Krishnasamy, Linda Mileshkin, Louis Irving, Sabine Braat, Ross A Clark, Ian Gordon, Linda Denehy
BACKGROUND: Lung cancer is one of the most commonly diagnosed cancers, and is a leading cause of cancer mortality world-wide. Due to lack of early specific symptoms, the majority of patients present with advanced, inoperable disease and five-year relative survival across all stages of non-small cell lung cancer (NSCLC) is 14%. People with lung cancer also report higher levels of symptom distress than those with other forms of cancer. Several benefits for survival and patient reported outcomes are reported from physical activity and exercise in other tumour groups...
September 29, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28954811/preclinical-characterization-of-r-3-3s-4s-3-fluoro-4-4-hydroxyphenyl-piperidin-1-yl-1-4-methylbenzyl-pyrrolidin-2-one-bms-986169-a-novel-intravenous-glutamate-n-methyl-d-aspartate-2b-glun2b-receptor-negative-allosteric-modulator-with-potential-in-major-depressive
#16
Linda J Bristow, Jyoti Gulia, Michael R Weed, Bettadapura N Srikumar, Yu-Wen Li, John D Graef, Pattipati S Naidu, Charulatha Sanmathi, Jayant Aher, Tanmaya Bastia, Mahesh Paschapur, Narasimharaju Kalidindi, Kuchibholta Vijaya Kumar, Thaddeus Molski, Rick Pieschl, Alda Fernandes, Jeffrey M Brown, Digavalli V Sivarao, Kimberly Newberry, Mark Bookbinder, Joseph Polino, Deborah Keavy, Amy Newton, Eric Shields, Jean Simmermacher, James Kempson, Jianqing Li, Huiping Zhang, Arvind Mathur, Raja Reddy Kallem, Meenakshee Sinha, Manjunath Ramarao, Reeba K Vikramadithyan, Srinivasan Thangathirupathy, Jayakumar Warrier, Joanne J Bronson, Richard E Olson, John E Macor, Charlie F Albright, Dalton King, Lorin A Thompson, Lawrence R Marcin, Michael Sinz
(R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), and the phosphate prodrug (BMS-986163), were identified from a drug discovery effort focused on the development of novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor (GluN2B) negative allosteric modulators for treatment resistant depression (TRD). BMS-986169 showed high binding affinity for the GluN2B subunit allosteric modulatory site (Ki = 4.03-6.3 nM) and selectively inhibited GluN2B receptor function in Xenopus oocytes expressing human N-methyl-D-aspartate receptor subtypes (IC50 = 24...
September 27, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28953812/study-on-lithium-monitoring-amongst-patients-in-a-community-mental-health-and-primary-care-setting-in-rural-england
#17
Nicholas Savage, Jessica Green, Madhavan Seshadri, Madhusudan Deepak Thalitaya
BACKGROUND: Lithium is widely used as a mood stabilizer in managing Bipolar Disorder. It is also licensed as an augmenting agent for recurrent depression and treatment resistant depression. However, it has a narrow therapeutic index with potentially significant side effects and adverse drug interactions. Toxicity is one of the main concerns for prescribers and serum levels should be checked regularly. Also, due to the adverse effects on Kidneys and Thyroid, there are strict guidelines to monitor the kidney as well as thyroid functions periodically...
September 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/28953038/an-open-label-pilot-study-of-combined-augmentation-with-creatine-monohydrate-and-5-hydroxytryptophan-for-selective-serotonin-reuptake-inhibitor-or-serotonin-norepinephrine-reuptake-inhibitor-resistant-depression-in-adult-women
#18
Brent M Kious, Hana Sabic, Young-Hoon Sung, Douglas G Kondo, Perry Renshaw
PURPOSE: Many women with major depressive disorder (MDD) respond inadequately to standard treatments. Augmentation of conventional antidepressants with creatine monohydrate and 5-hydroxytryptophan (5-HTP) could correct deficits in serotonin production and brain bioenergetics associated with depression in women, yielding synergistic benefit. We describe an open-label study of 5-HTP and creatine augmentation in women with MDD who had failed selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) monotherapy...
August 5, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28951141/maintenance-repetitive-transcranial-magnetic-stimulation-rtms-for-relapse-prevention-in-with-depression-a-review
#19
REVIEW
Fady Rachid
Major depressive disorder is a highly prevalent condition with significant morbidity and mortality. Recurrent episodes occur in greater than 50% of patients within a one year period despite treatment with antidepressant medications, electroconvulsive therapy and psychotherapy. Longer antidepressant treatment may prevent relapses and recurrences. Urgent therapeutic alternatives are needed such as maintenance repetitive transcranial magnetic stimulation. The purpose of this review is to describe and discuss studies that have evaluated the safety and efficacy of this technique in the long-term treatment and relapse prevention of depression...
September 19, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28950146/pikher2-a-phase-ib-study-evaluating-buparlisib-in-combination-with-lapatinib-in-trastuzumab-resistant-her2-positive-advanced-breast-cancer
#20
Mathilde Guerin, Keyvan Rezai, Nicolas Isambert, Mario Campone, Aurélie Autret, Jihane Pakradouni, Magali Provansal, Jacques Camerlo, Renaud Sabatier, François Bertucci, Emmanuelle Charafe-Jauffret, Alice Hervieu, Jean-Marc Extra, Patrice Viens, François Lokiec, Jean-Marie Boher, Anthony Gonçalves
BACKGROUND: Phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin pathway is frequently activated in HER2-positive breast cancer and may play a major role in resistance to trastuzumab. Buparlisib is a pan-class-I PI3K inhibitor with potent and selective activity against wild-type and mutant PI3K p110 isoforms. PATIENTS AND METHODS: PIKHER2 phase IB study aimed primarily to determine a maximum tolerated dose (MTD) and propose a recommended phase II dose (RP2D) for buparlisib in combination with lapatinib in HER2-positive, trastuzumab-resistant, advanced breast cancer...
September 23, 2017: European Journal of Cancer
keyword
keyword
13820
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"